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Abstract
Wernicke’s encephalopathy is caused by thiamine deficiency and has a range of presenting features, including gait
disturbance, altered cognitive state, nystagmus and other eye movement disorders. In the past, Wernicke’s encepha-
lopathy was described almost exclusively in the alcohol-dependent population. However, in current times, Wernicke’s
encephalopathy is also well recognized in many other patient groups, including patients following bariatric surgery,
gastrointestinal surgery, cancer and pancreatitis. Early recognition of Wernicke’s encephalopathy is vital, as prompt
treatment can restore cognitive or ocular function and can prevent permanent disability. Unfortunately, Wernicke’s
encephalopathy is often undiagnosed – presumably because it is relatively uncommon and has a variable clinical pre-
sentation. Clinical biochemists have a unique role in advising clinicians about potential nutritional or metabolic causes of
unexplained neurological symptoms and to prompt consideration of thiamine deficiency as a potential cause in high-risk
patient groups. The aim of this review is to summarize the clinical features, diagnosis and treatment of Wernicke’s
encephalopathy and to highlight some non-traditional causes, such as after bariatric surgery.
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Case report
A 26 year old woman presented to the department of
surgery with persistent vomiting six weeks after private
gastric sleeve surgery. During her admission, she was
found to have nystagmus, imbalance and gait distur-
bance, which was sufficiently severe to interfere with
activities of daily living, such as walking, reading and
watching television. A presumptive diagnosis of
Wernicke’s encephalopathy was made and a prolonged
course of high dose IV vitamin B1 (Pabrinex) caused a
gradual improvement in symptoms.
Introduction
Wernicke’s encephalopathy (WE), an acute neurologi-
cal disorder caused by thiamine (vitamin B1) deficiency,
is under-recognized and under-treated. Around 80% of
patients with the condition do not receive a diagnosis,
and many cases are only diagnosed postmortem. The
delay in identifying and treating the condition can be
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clinically disastrous as, untreated, WE can lead to per-
manent neurological damage, psychiatric sequelae and
death.
WE can be challenging to diagnose clinically or bio-
chemically. Presentation of one or more of the classic
triad of symptoms (described in Box 1) is highly sug-
gestive of the condition, but these features are not
always present. Previous studies found nearly a fifth
of confirmed WE cases did not display any of these
symptoms.1
Although classically, WE was described in the
alcohol-dependent population, there is increasing
awareness that other groups of patients, with no
history of alcohol dependence, can also suffer from
the condition. WE should be considered in patients
with other conditions affecting nutrition, including
hyperemesis gravidarum and following bariatric
surgery.
Terminology
The disease entity known as WE refers specifically to
the acute neurological disorder caused by thiamine
deficiency and is associated with the ‘classic triad’ of
symptoms (Box 1). Approximately half of patients who
survive WE will go on to develop chronic neuropsychi-
atric symptoms caused by thiamine deficiency, which is
known as Korsakoff’s syndrome.2,3 While the symp-
toms of WE can resolve with appropriate treatment,
Korsakoff’s syndrome is largely irreversible and is
characterized by global amnesia, confabulation,
apathy and disordered cognition.3 Due to the
common progression of WE to Korsakoff’s syndrome,
WE is sometimes referred to as ‘Wernicke–Korsakoff
syndrome’.
Thiamine deficiency can also cause other systemic
disorders. ‘Wet’ beriberi affects the cardiovascular
system and can cause congestive heart failure. ‘Dry’
beriberi refers to nervous system damage caused by
thiamine deficiency and includes polyneuropathy and
WE.4,5 Although dry and wet forms of beriberi can
occur in the same patient at the same time, this seems
to be rare.6
Epidemiology
Postmortem histological analyses have provided evi-
dence that WE occurs in about 1% of the general pop-
ulation and in 12.5–35.0% of alcohol-dependent
patients.7–9 Data about WE prevalence throughout
the world are limited, but available information indi-
cates that the country-wide prevalence of the disease is
not linked to per capita alcohol consumption
(Figure 1).5,10,11 WE due to alcohol misuse is more
common in males (1.69 males for each female patient),
while non-alcohol related causes are more common in
females (1.84 females for each male patient). The age of
onset of WE also differs with disease causation. The
average age of onset of the condition in alcohol-
dependent patients is over 40 years old, while non-
alcohol related causes are more common in younger
age groups.2,12
Thiamine deficiency and human disease
Unlike plants and microbes, animals are unable to syn-
thesize thiamine and thus are reliant on dietary sources
to meet requirements. Humans require between 1 and
2mg of thiamine daily from the diet and have total
body thiamine stores of around 30–50mg. Therefore,
stores can be exhausted anywhere between 18 days and
6weeks with a thiamine-deficient or -devoid diet.13,14
Compared to other animals, humans have much lower
brain thiamine concentrations: there is a 20 pmol/mg
concentration of the bioactive form of thiamine in
human brains, while certain primates have double
this concentration and rodents have concentrations
greater than 115 pmol/mg.15,16 The susceptibility of
humans to thiamine deficiency is well-established, and
many countries actively fortify foods such as bread and
grains with thiamine.17,18
Although healthy people are susceptible to thiamine
deficiency, certain medical conditions can increase the
chances of developing thiamine deficiency and WE.
These conditions are associated with decreased access,
absorption, storage capability, impaired cellular utili-
zation of thiamine, or increased metabolism or loss of
thiamine.
The pathology of thiamine deficiency
Mechanisms of pathological sequelae from
thiamine deficiency
WE results from a lack of thiamine (vitamin B1) avail-
ability. Thiamine in its bioactive form thiamine pyro-
phosphate (TPP, also called thiamine diphosphate) is
necessary for energy metabolism in all cells. TPP acts as
a cofactor for transketolase in the pentose phosphate
Box 1. Classical symptoms of Wernicke’s encephalopathy.
1. Altered mental state and/or memory deficit
2. Nystagmus, ophthalmoplegia or other disordered eye
movements
3. Ataxia/gait disturbance
Kohnke and Meek 39
pathway, as a cofactor for pyruvate dehydrogenase in
the transition from glycolysis to the tricarboxylic acid
(TCA) cycle and as a cofactor for a-ketoglutarate dehy-
drogenase within the TCA cycle (Figure 2). Thiamine
deficiency therefore disrupts cellular metabolism in sev-
eral ways and limits the availability of ATP. It is
thought the brain is the main site of damage due to
its immense energy requirement compared to the rest
of the body.19,20
The exact cause of brain damage in WE is unclear,
but may be related to focal lactic acidosis, disruption of
the blood–brain barrier, neural cell excitotoxicity,
inflammation or insufficient amounts of cellular ATP.
Brain lesions in WE are often attributed to focal
lactic acidosis.5,21,22 When thiamine is not available
to facilitate pyruvate conversion through the TCA
cycle, pyruvate accumulates within the cell. The con-
centrations of pyruvate and lactate are normally at
equilibrium, and an increase in pyruvate causes a sub-
sequent increase in lactate concentration (Figure 2).23
Increased lactate from thiamine deficiency causes a fall
in pH in specific parts of the brain which are also
affected in experimental animal models of WE.24,25
The idea that disruption of the blood–brain barrier
may be a cause of WE lesions was first introduced in
1949.26 Increased permeability of the blood–brain bar-
rier can allow large proteins not normally found in the
central nervous system to pass into the brain and puts
neurological tissue at risk of toxic effects. Several
regions of the brain typically found to have lesions in
WE are at blood–brain barrier junctions.27
Another proposed mechanism includes neural cell
excitotoxicity, which is caused by extracellular build-
up of glutamate. In thiamine deficiency, glutamate
transporters in astrocytes (which normally clear the
synapse of released glutamate by facilitating astrocyte
uptake of the neurotransmitter) are downregulated,
leading to sustained depolarization of neurons and sub-
sequent death of the cells.28,29 Inflammation is also
known to occur in thiamine deficiency, with microglial
reactivity and pro-inflammatory cytokines found
throughout the brain.30 However, the pathological
effects of this are unknown.
Medical conditions associated with WE
WE is classically considered a disease of alcohol-
dependent patients. However, there are many other
conditions that increase the likelihood of developing
thiamine deficiency in patients with no history of alco-
hol misuse. These conditions are associated with
decreased access, absorption, storage capability or cel-
lular utilization of thiamine, or increased metabolism
or loss of thiamine.
Conditions of decreased access to thiamine
Thiamine deficiency and subsequent WE can occur
when a person’s diet is deficient or devoid of thiamine.
Figure 1. Epidemiology of WE. (a) Incidence of WE is estimated to be less than 1% in the general population and 12.5% in alcohol-
dependent patients. (b) The ratio of males and females with WE differs depending on cause of the disease. For non-alcohol-related
causes, females outnumber males 1.69:1, while males with alcohol-related WE outnumber females 1.84:1. (c) Australia, Austria, Brazil,
France, Germany, Norway and the United States have documented the prevalence of WE based on autopsies with average ranges
from 0.6 to 2.2%.
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For example, WE has been documented after food dep-
rivation during anorexia nervosa, religious fasting and
malnutrition in the elderly.31–33 Lack of thiamine sup-
plementation during total parenteral nutrition is anoth-
er cause of WE.34 Conditions that cause nausea and
vomiting are also linked to development of WE: hyper-
emesis gravidarum is a well-documented cause of the
condition.35,36
Conditions of decreased gastrointestinal (GI)
absorption of thiamine
Thiamine from food is hydrolysed into free thiamine by
phosphatases in the lumen of the intestine.17 Free thi-
amine is then absorbed by the mucosa of the small
intestine and converted to TPP in erythrocytes, then
carried to stores in the liver, skeletal muscle, heart
and kidney (Figure 3).37–40 In experimental animals,
alcohol use has been shown to directly inhibit thiamine
absorption in the GI tract.41,42 In humans, conditions
that commonly disrupt nutrient absorption include
Crohn’s disease, pyloric stenosis, peptic ulcers or
chronic diarrhoea, which have all been linked to devel-
opment of WE.43–46
Bariatric and GI surgery accounts for a large pro-
portion of cases of WE due to decreased thiamine
absorption.2 Cases of WE after bariatric surgery for
weight loss have greatly increased in the past two dec-
ades.47 These operations often lead to both decreased
access to thiamine and decreased absorption of thia-
mine. Patients often experience postoperative vomiting
which reduces thiamine intake, and certain procedures,
like Roux-en-Y gastric bypass, reduce thiamine absorp-
tion by reducing the length of the gut available for
nutrient absorption.48
Conditions of decreased thiamine storage capability
Thiamine is mainly stored in the liver.49,50 Conditions
such as end-stage chronic liver failure are associated
with depleted stores of thiamine and can lead to
WE.51 This phenomenonmay be exacerbated by regular
alcohol use, as long-term administration of alcohol to
experimental animals has been shown to cause dimin-
ished thiamine stores in both the brain and liver.52
Conditions of impaired cellular thiamine utilization
Genetic variants may cause disruption to cellular utili-
zation of thiamine. The majority of studies on genetic
susceptibility to WE have focused on heritable dysfunc-
tions in the transketolase enzyme. This enzyme binds
with TPP in the pentose phosphate pathway (Figure 2).
In some patients with WE, transketolase activity is
impaired in likely a heritable manner, possibly by
altered affinity of the enzyme to TPP.53,54 In those
with altered transketolase binding, even vitamin sup-
plementation may not be enough to overcome reduced
transketolase activity.54,55
Conditions of increased use/disposal of thiamine
Many patients with WE will have more than one con-
tributing cause of thiamine deficiency, such as reduced
thiamine intake and increased thiamine requirements.
However, certain conditions cause increased metabo-
lism or loss of thiamine itself. A large dietary carbohy-
drate load, a hypermetabolic state (such as
hyperthyroidism) or certain rapidly growing cancers
increase thiamine requirements and cause rapid
depletion of body thiamine stores.56–58 Additionally,
Figure 2. The bioactive form of thiamine is necessary for sev-
eral cellular processes. TPP is the bioactive form of thiamine. It is
a necessary cofactor in the pentose phosphate pathway, glycol-
ysis and the TCA cycle. Additionally, it plays a role in maintaining
equilibrium between pyruvate and lactate. TCA: tricarboxylic
acid; TPP: thiamine pyrophosphate.
Kohnke and Meek 41
haemodialysis or peritoneal dialysis can promote accel-
erated loss of water-soluble vitamins such as thia-
mine.59,60 Administration of B vitamins should be
considered in high-risk patients, including those on
dialysis and when refeeding a malnourished patient.
WE – a challenging diagnosis
WE is challenging to diagnose and many cases are iden-
tified on postmortem examination.5,56 Presentations of
the disease vary widely between cases, and often the
signs are subtle or absent.
Clinical signs
The diagnosis of WE can be made clinically, based on
the presence of the ‘classical triad’ of symptoms
(Box 1). Caine and colleagues developed a proposed
set of criteria for WE diagnosis which requires at





• Mild memory impairment or altered mental state.
Caine et al.61 reported a sensitivity of 94% and spe-
cificity of 99% for the diagnosis of WE when these
criteria were used. However, clinical presentation can
differ greatly in individuals with WE. One study
showed only 44% of those with postmortem WE diag-
nosis displayed two or more operational criteria before
death.1 Due to the common absence of clinical signs,
several other methods are employed to aid diagnosis.
Biochemistry
Testing whole blood or erythrocytes for thiamine con-
tent is a very useful confirmatory test for thiamine defi-
ciency in patients with suspected WE. However, these
tests are not available in most clinical laboratories and
treatment cannot be delayed to wait for the result.
Ideally, when the diagnosis is suspected, blood draw
before treatment is given is likely to maximize the like-
lihood of obtaining a diagnostically useful result.10
TPP, the active form of thiamine, is carried from the
intestine to thiamine-storing organs via erythrocytes
(Figure 3). Historically, assays for blood transketolase
activity as an indirect measurement of TPP content
have been used to assess thiamine deficiency.62
However, direct measurement of TPP or thiamine via
high performance liquid chromatography has been
shown to be more precise and robust.63,64 There is
some controversy about reference ranges for thiamine,
as some variation between regions is to be expected
based on different dietary and environmental factors.
Local laboratories normally obtain reference values
from non-thiamine-deficient patients’ samples.63,65
MRI scans
When WE is suspected in the absence (or even presence)
of clinical signs, an MRI scan can be useful to assess if
there are neurological abnormalities. As with clinical
signs, the brain areas presented with damage in these
scans vary widely from person to person. ‘Typical’
lesions found in MRI scans are seen in only 58% of
patients. In these patients, an increased T2 signal (signi-
fying oedema) can be found in the paraventricular
regions of the thalamus and hypothalamus and the peri-
aqueductal region, while the cerebellum and mamillary
bodies may be reduced in size. To detect WE, MRI has a
sensitivity of 53% but a specificity of 93%.66 Ideally,
MRI will be performed before thiamine administration,
as brain abnormalities are quickly reversed after treat-
ment has begun.67 However, the need for urgent treat-
ment often makes this impossible.
Diagnosis at postmortem examination
As clinical signs are variable, the diagnosis of WE is
often made postmortem. On macroscopic examination
of the brain, shrunken and discoloured mamillary
bodies are the most common abnormality, seen in
around 80% of patients affected by WE. Atrophy of
the cerebellum and dilation of ventricles are also
common, and lesions are usually found near the ven-
tricular system. Microscopically, common features of
WE include increased numbers of blood vessels and
gliosis in the mamillary bodies. Other histological fea-
tures of brain tissue in affected patients include micro-
haemorrhages, gliosis, axon and myelin damage, and
significant loss of cerebellar Purkinje cells.68,69
Diagnostic challenges
It is often necessary to combine tests to increase the
likelihood of making the diagnosis, but even multiple
tests may not be enough to confirm a positive diagno-
sis. Treatment for WE is often begun before a diagnosis
is confirmed. Many consider reversal of clinical signs
upon treatment with thiamine to be the best support
for an antemortem diagnosis of WE.5
WE – a simple treatment
Thiamine treatment
Due to the rapid progression of WE, it is recommended
that therapeutic administration of thiamine be com-
menced in any case where thiamine deficiency is
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suspected, even before a firm diagnosis has been made.
As patients may have impaired mechanisms to absorb
the vitamin via the GI tract, parenteral administration
is necessary.13 Vitamin B1 has an extremely low risk of
adverse effects (anaphylactic shock was reported in
four cases in one million intravenous administrations
and one case in five million intramuscular administra-
tions), therefore the potential gains from administra-
tion to a patient with possible thiamine deficiency far
outweigh the risks of not treating the condition.70
There is no consensus on the dosing or duration of
vitamin B1 to treat WE, although those with WE
caused by alcohol use may need higher daily doses.
The European Federation of Neurological Societies
recommends intravenous administration of 200mg thi-
amine three times daily until there are no additional
improvements in clinical conditions, while British
authors have recommended 500mg three times per
day for 2–3 days then 250mg daily until improvements
cease.5,10
Vitamin B1 as prophylaxis
The use of vitamin B1 as prophylaxis is widespread
internationally. Many countries fortify food with thia-
mine.71 Many hospitals use thiamine administration
prophylactically for high-risk groups, including
patients with malnutrition, hypoglycaemia or alcohol
dependence.10,60,72 Recent studies have questioned this
practice, however, providing evidence that there was no
difference between administering thiamine before or
after short-term glucose treatment.72,73 Patients with
a history of bariatric surgery are advised to take pro-
phylaxis indefinitely due to decreased ability to absorb
thiamine. One author recommends doses of 50–100mg
orally three times per day.74
Case report outcome
Our patient initially was treated with 250mg thiamine
intravenously three times daily (given as Pabrinex)
Figure 3. Modification and transport of thiamine from food. Thiamine derived from food sources is hydrolysed into free thiamine in
the lumen of the intestine. Free thiamine is passed through the intestinal wall to erythrocytes where it is converted to the bioactive
form of thiamine – TPP. Blood carries TPP to organs such as the liver, heart, etc. To pass into the brain, TPP must cross the blood–brain
barrier into the cerebrospinal fluid of the central nervous system before it diffuses throughout the brain. CSF: cerebrospinal fluid.
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which stabilized her symptoms but did not entirely
resolve them. She responded more quickly to 500mg
thiamine three times daily, and her symptoms
improved markedly over several weeks. Biochemistry
and MRI results were inconclusive, but both tests
had been initiated after the onset of treatment. The
improvement to early administration of thiamine was
considered consistent with the diagnosis, in a patient
with recognized risk factors.
Early treatment did improve her symptoms, but they
did not resolve entirely. At their peak, her symptoms
were extremely disabling and included difficulties read-
ing mobile phone messages or watching television. She
had poor balance and could not walk unattended
around the ward. Chronic disability appeared a likely
long-term outcome. However, after many weeks of
high dose thiamine treatment, her symptoms gradually
subsided and she was able to start physiotherapy to
improve mobility in preparation for discharge.
Overall, her recovery was slower than expected, per-
haps due to her frequent vomiting episodes which lim-
ited dietary thiamine replacement. Her vomiting
episodes gradually settled with educational input
about eating styles and food choices after bariatric sur-
gery. She has now returned to work and remains on
lifelong oral thiamine supplementation with regular
nutritional follow-up in a specialist postbariatric clinic.
In general, our patient was very fortunate to avoid
chronic neurological sequelae and long-term disability.
Sadly, the prognosis in WE is often poor, with around
50% of patients having long-term consequences,
including memory impairment or Korsakoff’s syn-
drome.2,3 In patients with WE due to alcohol depen-
dence, around 80% will develop Korsakoff’s
syndrome, and around 40% could die as a complica-
tion of Wernicke–Korsakoff syndrome.2,12 However,
even among patients with a non-alcohol-related
cause, only around 20% of patients make a complete
recovery while a further 20% may die due to compli-
cations of the disease.
Conclusions
WE is a serious and underdiagnosed disease.
Historically thought to be a disease of alcohol
misuse, it is now well recognized that many conditions
can cause WE. WE after bariatric surgery is increasing-
ly common and clinical biochemists have a unique
opportunity to make sure the diagnosis is considered
when a patient presents with unexplained neurological
features. The diagnosis of WE is difficult and requires
integration of clinical signs, MRI appearance and bio-
chemistry results, and is complicated by the urgent
need to start treatment before confirming the diagnosis.
Thiamine is a safe and effective treatment and should
be given prophylactically to high-risk groups. The
prognosis for those who have experienced WE remains
poor, especially for those with an alcohol-related cause,
and relatively few patients make a full recovery.
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